Twenty-four Staphylococcus species and their subspecies were examined for their susceptibilities to teicoplanin by disk diffusion (30-,ug disk) and agar dilution for the determination of MICs. Moderately susceptible and resistant clinical strains were further tested for their susceptibilities to oxacillin and vancomycin. Teicoplanin resistance was not observed in the reference strains of the various Staphylococcus species isolated from healthy volunteers or animals. However, the novobiocin-resistant species Staphylococcus saprophyticus, Staphylococcus cohnii, Staphylococcus xylosus, Staphylococcus arlettae, Staphylococcus kloosii, and Staphylococcus gallinarum were less susceptible to teicoplanin (MIC, 2 to 8 ,ug/ml) than most of the novobiocin-susceptible species were (MIC, 0.5 to 4 ,Ig/ml). Clinical isolates of coagulase-negative species were generally less susceptible to teicoplanin than were reference strains. Seven percent of the Staphylococcus epidermidis clinical strains were moderately susceptible (MIC, 16 , u.g/ml) to teicoplanin. Of these strains, 70% were oxacillin resistant. For Staphylococcus haemolyticus strains, 11% were resistant (MIC, >16 ,ug/ml) and 21% were moderately susceptible to teicoplanin. Of these strains, 95% were oxacillin resistant. No strains of S. epidermidis or S. haemolyticus were intermediate or resistant to vancomycin. Teicoplanin appears to be less active in vitro against oxacillin-resistant S. haemolyticus. However, teicoplanin is an effective antimicrobial agent against many Staphylococcus species.
The frequent isolation of clinically significant Staphylococcus species is a major concern for the medical community. In the past, patients were commonly treated with various penicillins, erythromycin, clindamycin, and/or gentamicin for staphylococcal infections. However, owing to many factors, including the extensive use of these antibiotics, staphylococci have developed resistant populations (17) . For this reason, new antibiotics are being developed and tested on Staphylococcus species.
Teicoplanin is a glycopeptide that targets the peptidoglycan synthesis of gram-positive bacteria (8, 15) . It is considered by some to be a drug of choice for the treatment of severe infections caused by antibiotic-resistant, gram-positive bacteria, especially the coagulase-negative staphylococci which often produce infections that are difficult to manage.
In this study, 24 Staphylococcus species and 4 subspecies were tested for their susceptibilities to teicoplanin by disk diffusion and agar dilution for the determination of MICs. The moderately susceptible and resistant clinical strains were tested further for their susceptibilities to oxacillin and vancomycin.
(A preliminary report of this work was presented previously [2] .)
Reference strains of the 24 Staphylococcus species and their subspecies were obtained from our laboratory's collection of isolates from the skin of healthy human volunteers or animals. The clinical strains used in this study were isolated from a variety of patients at Rex Hospital, Raleigh, N.C. All the clinical strains were identified by using the criteria of Kloos and coworkers (10, 11 For the purpose of this study, the criteria for the determination of susceptibility, moderate susceptibility, and resistance to teicoplanin were the breakpoints tentatively accepted by the NCCLS Subcommittee on Antimicrobial Susceptibility Testing in June 1991: susceptible, MIC of c8 Fxg/ml and zone of inhibition of .14 mm; moderately susceptible, MIC of 16 ,ug/ml and zone of inhibition of 11 to 13 mm; and resistant, MIC of >16 ,ug/ml and zone of inhibition of '10 mm (3, 4) . The criteria for oxacillin and vancomycin susceptibility were those recommended by NCCLS (13, 14) .
A total of 332 reference strains of staphylococci were analyzed for their susceptibilities to teicoplanin (Table 1) . Mean MICs for the novobiocin-resistant species S. saprophyticus, S. cohnii, S. xylosus, S. arlettae, S. kloosii, and S. gallinarum ranged from 2 to 8 ,ug/ml, and these species were less susceptible to teicoplanin than were the novobiocinsusceptible species (MIC, 0.5 to 4 ,ug/ml). The disk diffusion data also supported this finding. A total of 474 clinical strains of staphylococci were analyzed for their susceptibilities to teicoplanin ( Table 1) . The clinical isolates were generally less susceptible to teicoplanin than the reference strains of the same species or subspecies were. MICs for clinical strains ranged from 1 to 8 j.ag/ml, whereas MICs for reference strains ranged from c0.5 to 4 jig/ml. The difference in MICs is shown in Fig. 1 . Mean MICs for clinical and reference strains of S. haemolyticus demonstrated the largest difference. Even though the clinical isolates were less susceptible than the reference strains, the majority of the strains were still, by definition, susceptible to teicoplanin. Several clinical strains of S. epidermidis and S. haemolyticus that showed either moderate susceptibility or resistance were isolated (1, 7, 9, 12) . Of 312 strains of S. epidermidis, 23 strains (7.4%) were moderately susceptible by MIC determination. Of these strains, only seven were moderately susceptible by disk diffusion. Of 62 strains of S. haemolyticus, 7 strains (11%) were resistant and 14 strains (23%) were moderately susceptible by MIC determination. Of the resistant strains described above, none were resistant by disk diffusion, but five were moderately susceptible by disk diffusion. Of the 14 moderately susceptible strains by MIC determination, 11 were moderately susceptible by disk diffusion. The 23 strains of S. epidermidis that were moderately susceptible to teicoplanin were analyzed for their susceptibilities to oxacillin. Sixteen strains (70o) were oxacillin resistant. Of the strains of S. haemolyticus that were either moderately susceptible or resistant to teicoplanin, 20 strains (95%) were oxacillin resistant (5, 6, 8, 12 
